Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 16 | 2020 | 2209 | 1.41 | Why? |
| HIV Infections | 29 | 2020 | 11620 | 1.01 | Why? |
| Heterocyclic Compounds, 3-Ring | 7 | 2019 | 275 | 0.80 | Why? |
| Darunavir | 5 | 2020 | 477 | 0.58 | Why? |
| Lamivudine | 3 | 2019 | 210 | 0.49 | Why? |
| Atazanavir Sulfate | 3 | 2018 | 213 | 0.45 | Why? |
| Ritonavir | 7 | 2020 | 4212 | 0.40 | Why? |
| Quinolones | 3 | 2020 | 167 | 0.37 | Why? |
| HIV Integrase Inhibitors | 3 | 2019 | 173 | 0.37 | Why? |
| HIV-1 | 12 | 2020 | 3365 | 0.36 | Why? |
| Antiretroviral Therapy, Highly Active | 6 | 2020 | 952 | 0.35 | Why? |
| Carbamyl Phosphate | 1 | 2004 | 1 | 0.30 | Why? |
| Reverse Transcriptase Inhibitors | 2 | 2018 | 309 | 0.30 | Why? |
| Foscarnet | 1 | 2004 | 13 | 0.30 | Why? |
| Carbonic Anhydrase Inhibitors | 1 | 2004 | 31 | 0.29 | Why? |
| HIV Protease Inhibitors | 2 | 2018 | 434 | 0.28 | Why? |
| Oxazines | 7 | 2019 | 279 | 0.28 | Why? |
| Phosphates | 1 | 2004 | 135 | 0.27 | Why? |
| Piperazines | 7 | 2019 | 445 | 0.25 | Why? |
| Anti-Retroviral Agents | 3 | 2020 | 1099 | 0.23 | Why? |
| Pyridones | 7 | 2019 | 738 | 0.21 | Why? |
| Raltegravir Potassium | 2 | 2019 | 132 | 0.20 | Why? |
| Drug Therapy, Combination | 9 | 2020 | 7268 | 0.20 | Why? |
| Emtricitabine | 2 | 2018 | 202 | 0.20 | Why? |
| Cobicistat | 2 | 2019 | 172 | 0.20 | Why? |
| Tenofovir | 3 | 2018 | 449 | 0.20 | Why? |
| Endothelial Progenitor Cells | 1 | 2020 | 103 | 0.19 | Why? |
| Nevirapine | 1 | 2018 | 57 | 0.19 | Why? |
| Calcaneus | 1 | 2018 | 13 | 0.18 | Why? |
| Infertility, Female | 1 | 2020 | 150 | 0.18 | Why? |
| HIV Seroprevalence | 1 | 2017 | 16 | 0.18 | Why? |
| Lipodystrophy | 1 | 2017 | 18 | 0.18 | Why? |
| AIDS Dementia Complex | 1 | 2018 | 48 | 0.18 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.18 | Why? |
| Cyclohexanes | 1 | 2017 | 43 | 0.17 | Why? |
| Bone Diseases, Metabolic | 1 | 2018 | 64 | 0.17 | Why? |
| Virus Replication | 1 | 2019 | 14331 | 0.17 | Why? |
| Toll-Like Receptor 7 | 1 | 2021 | 402 | 0.17 | Why? |
| Virus Latency | 1 | 2019 | 251 | 0.16 | Why? |
| HIV Seropositivity | 1 | 2019 | 320 | 0.16 | Why? |
| Syphilis | 1 | 2020 | 318 | 0.16 | Why? |
| Italy | 18 | 2021 | 38444 | 0.15 | Why? |
| Drug Resistance, Viral | 2 | 2020 | 1083 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Adenine | 1 | 2018 | 463 | 0.14 | Why? |
| Papillomavirus Vaccines | 1 | 2020 | 405 | 0.14 | Why? |
| Delayed-Action Preparations | 1 | 2017 | 291 | 0.14 | Why? |
| Viral Load | 8 | 2020 | 15850 | 0.14 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.13 | Why? |
| Retina | 1 | 2018 | 424 | 0.13 | Why? |
| CD4 Lymphocyte Count | 4 | 2020 | 1517 | 0.13 | Why? |
| Triazoles | 1 | 2017 | 440 | 0.13 | Why? |
| Patients | 1 | 2021 | 1167 | 0.12 | Why? |
| Appointments and Schedules | 1 | 2021 | 1204 | 0.12 | Why? |
| Osteoporosis | 1 | 2018 | 410 | 0.12 | Why? |
| Papillomavirus Infections | 1 | 2020 | 861 | 0.12 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.11 | Why? |
| Dyslipidemias | 1 | 2017 | 791 | 0.11 | Why? |
| Hyperglycemia | 1 | 2021 | 1363 | 0.10 | Why? |
| Apoptosis | 1 | 2020 | 2335 | 0.10 | Why? |
| Molecular Targeted Therapy | 1 | 2019 | 1579 | 0.10 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.09 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.09 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.09 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 1510 | 0.09 | Why? |
| Treatment Failure | 3 | 2019 | 2106 | 0.09 | Why? |
| Lost to Follow-Up | 2 | 2017 | 79 | 0.09 | Why? |
| Genomics | 1 | 2020 | 3118 | 0.09 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2021 | 3607 | 0.09 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.08 | Why? |
| Blood Glucose | 1 | 2021 | 3642 | 0.08 | Why? |
| Health Status | 1 | 2020 | 3259 | 0.08 | Why? |
| Cohort Studies | 9 | 2021 | 36005 | 0.08 | Why? |
| Hospitalization | 4 | 2020 | 54280 | 0.08 | Why? |
| Carbonic Anhydrase IV | 1 | 2004 | 2 | 0.08 | Why? |
| Carbonic Anhydrase V | 1 | 2004 | 2 | 0.08 | Why? |
| Humans | 41 | 2021 | 930598 | 0.08 | Why? |
| Ambulatory Care Facilities | 1 | 2017 | 2063 | 0.07 | Why? |
| Male | 27 | 2021 | 367725 | 0.07 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.07 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.07 | Why? |
| Female | 27 | 2020 | 380317 | 0.07 | Why? |
| Isoenzymes | 1 | 2004 | 127 | 0.07 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.07 | Why? |
| Drug Discovery | 1 | 2019 | 3092 | 0.07 | Why? |
| Adult | 21 | 2021 | 244371 | 0.07 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.06 | Why? |
| RNA, Viral | 6 | 2020 | 32276 | 0.06 | Why? |
| Coronavirus | 3 | 2020 | 18339 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.06 | Why? |
| Regression Analysis | 2 | 2020 | 2484 | 0.06 | Why? |
| Cardiovascular Diseases | 2 | 2017 | 11497 | 0.06 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.06 | Why? |
| CD146 Antigen | 1 | 2020 | 19 | 0.06 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.05 | Why? |
| HIV | 2 | 2018 | 1116 | 0.05 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.05 | Why? |
| Sitagliptin Phosphate | 1 | 2020 | 82 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2020 | 12447 | 0.05 | Why? |
| Transaminases | 1 | 2020 | 152 | 0.05 | Why? |
| Alphapapillomavirus | 1 | 2020 | 107 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2020 | 6166 | 0.05 | Why? |
| Drug Combinations | 2 | 2020 | 3852 | 0.05 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.05 | Why? |
| Insulin-Secreting Cells | 1 | 2021 | 273 | 0.05 | Why? |
| Growth Hormone-Releasing Hormone | 1 | 2017 | 17 | 0.05 | Why? |
| Self Report | 2 | 2020 | 3802 | 0.04 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.04 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.04 | Why? |
| Maximum Tolerated Dose | 1 | 2017 | 65 | 0.04 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| CD4-CD8 Ratio | 1 | 2018 | 235 | 0.04 | Why? |
| Salvage Therapy | 1 | 2018 | 417 | 0.04 | Why? |
| Insulin Resistance | 1 | 2021 | 669 | 0.04 | Why? |
| Treatment Outcome | 5 | 2020 | 51732 | 0.04 | Why? |
| Genetic Predisposition to Disease | 2 | 2021 | 4027 | 0.04 | Why? |
| Bone Density | 1 | 2018 | 335 | 0.04 | Why? |
| Cholesterol, HDL | 1 | 2018 | 439 | 0.03 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.03 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.03 | Why? |
| Health Services Accessibility | 1 | 2017 | 10697 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.03 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.03 | Why? |
| Risk Factors | 5 | 2020 | 71621 | 0.03 | Why? |
| Aged | 8 | 2020 | 215776 | 0.03 | Why? |
| Animals | 2 | 2019 | 78931 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Cross-Sectional Studies | 4 | 2020 | 53120 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2019 | 25288 | 0.03 | Why? |
| Sexual Behavior | 1 | 2020 | 1322 | 0.03 | Why? |
| History, 20th Century | 1 | 2017 | 1282 | 0.03 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Tomography, Optical Coherence | 1 | 2018 | 1008 | 0.03 | Why? |
| Sexual and Gender Minorities | 1 | 2020 | 1019 | 0.03 | Why? |
| Lipids | 1 | 2017 | 1079 | 0.03 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.03 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.02 | Why? |
| Safety | 1 | 2017 | 1583 | 0.02 | Why? |
| Health Surveys | 1 | 2020 | 2841 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| HEK293 Cells | 1 | 2021 | 8394 | 0.02 | Why? |
| Data Collection | 1 | 2017 | 1769 | 0.02 | Why? |
| Republic of Korea | 1 | 2020 | 5858 | 0.02 | Why? |
| Pyrazines | 1 | 2017 | 1783 | 0.02 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2017 | 1671 | 0.02 | Why? |
| Survival Analysis | 1 | 2019 | 7592 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Computational Biology | 1 | 2020 | 4514 | 0.02 | Why? |
| Databases, Factual | 1 | 2020 | 6248 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Mutation | 1 | 2020 | 12376 | 0.01 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Stress, Psychological | 1 | 2021 | 10231 | 0.01 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.01 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Vaccination | 1 | 2020 | 19050 | 0.01 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
Rusconi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(182)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(236)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_